Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification

Journal of Cataract and Refractive Surgery

Volumn 38, Issue 9, 2012, Pages 1537-1543

  Almeida, David R P ^a   Khan, Zainab ^a   Xing, Lin ^a   Bakar, Shahrukh N ^a   Rahim, Karim ^a   Urton, Todd ^a   El Defrawy, Sherif R ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

KETOROLAC; NEPAFENAC; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE;

ADULT; AGED; ARTICLE; BLURRED VISION; BURN; CATARACT; CATARACT EXTRACTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; DRY EYE; EYE REDNESS; EYELID DISEASE; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; LENS IMPLANT; MAJOR CLINICAL STUDY; MALE; OCULAR PRURITUS; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PHACOEMULSIFICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA EDEMA; SUSPENSION; SWELLING; TASTE DISORDER; THICKNESS;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZENEACETAMIDES; DOUBLE-BLIND METHOD; FEMALE; HEALTH STATUS; HUMANS; KETOROLAC; MACULAR EDEMA; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PHACOEMULSIFICATION; PHENYLACETATES; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME;

EID: 84865275021     PISSN: 08863350     EISSN: 18734502     Source Type: Journal    
DOI: 10.1016/j.jcrs.2012.04.034     Document Type: Article

References (19)

1. K. Miyake, and N. Ibaraki Prostaglandins and cystoid macular edema Surv Ophthalmol 47 suppl 1 2002 S203 S218
2. H. Ozdemir, S. Karacorlu, and M. Karacorlu Postoperative subretinal fluid associated with cystoid macular edema following cataract surgery Retina 25 2005 223 225 (Pubitemid 40365953)
3. K. Miyake Indomethacin in the treatment of postoperative cystoid macular edema Surv Ophthalmol 28 1984 554 568 (Pubitemid 14076516)
4. M. Ahuja, A.S. Dhake, S.K. Sharma, and D.K. Majumdar Topical ocular delivery of NSAIDs AAPS J 10 2008 229 241 Available at: http://www.ncbi.nlm.nih. gov/pmc/articles/PMC2751374/pdf/12248-2008-Article-9024.pdf Accessed June 1, 2012
5. K. Miyake Nonsteroidal anti-inflammatory agents in cataract intraocular lens surgery [editorial review] Curr Opin Ophthalmol 6 1 1995 62 65
6. T.-L. Ke, G. Graff, J.M. Spellman, and J.M. Yanni Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers Inflammation 24 2000 371 384
7. K.D. Solomon, J.K. Cheetham, R. DeGryse, S.F. Brint, and A. Rosenthal Topical ketorolac tromethamine 0.5% ophthalmic solution in ocular inflammation after cataract surgery Ophthalmology 108 2001 331 337 (Pubitemid 32115965)
8. E.D. Donnenfeld, E.J. Holland, R.H. Stewart, J.A. Gow, L.R. Grillone Bromfenac Ophthalmic Solution 0.09% (Xibrom) Study Group Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation Ophthalmology 114 2007 1653 1662
9. S.S. Lane, S.S. Modi, R.P. Lehmann, and E.J. Holland Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery J Cataract Refract Surg 33 2007 53 58 erratum, 564 (Pubitemid 46001537)
10. M.C. Kraff, R.G. Martin, A.C. Neumann, and A.J. Weinstein Efficacy of diclofenac sodium ophthalmic solution versus placebo in reducing inflammation following cataract extraction and posterior chamber lens implantation J Cataract Refract Surg 20 1994 138 144 (Pubitemid 24100165)
11. S.M. El-Harazi, R.S. Ruiz, R.M. Feldman, G. Villanueva, and A.Z. Chuang A randomized double-masked trial comparing ketorolac tromethamine 0.5%, diclofenac sodium 0.1%, and prednisolone acetate 1% in reducing post-phacoemulsification flare and cells Ophthalmic Surg Lasers 28 1998 539 544
12. A.J. Flach, B.J. Dolan, M.E. Donahue, E.G. Faktorovich, and G.A. Gonzalez Comparative effects of ketorolac 0.5% or diclofenac 0.1% ophthalmic solutions on inflammation after cataract surgery Ophthalmology 105 1998 1775 1779 (Pubitemid 28513535)
13. J.S. Heier, T.M. Topping, W. Baumann, M.S. Dirks, and S. Chern Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema Ophthalmology 107 2000 2034 2038 discussion by AJ Flach, 2039
14. J.R. Wittpenn, S. Silverstein, J. Heier, K.R. Kenyon, J.D. Hunkeler, M. Earl Acular LS for Cystoid Macular Edema (ACME) Study Group A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low-risk cataract surgery patients Am J Ophthalmol 146 2008 554 560
15. D.R.P. Almeida, D. Johnson, H. Hollands, D. Smallman, S. Baxter, K.T. Eng, V. Kratky, M.W. ten Hove, S. Sharma, and S. El-Defrawy Effect of prophylactic nonsteroidal antiinflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgery J Cataract Refract Surg 34 2008 64 69
16. T.P. O'Brien Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care Curr Med Res Opin 21 2005 1131 1137 erratum, 1431-1432 (Pubitemid 41032705)
17. B.L. Barber, E.R. Strahlman, R. Laibovitz, H.A. Guess, and S.A. Reines Validation of a questionnaire for comparing the tolerability of ophthalmic medications Ophthalmology 104 1997 334 342 (Pubitemid 27088113)
18. National Institutes of Health Clinical Trials. Prophylactic Nepafenac and Ketorolac Versus Placebo in Patients Undergoing Cataract Surgery (PNK). NCT0139069. Available at: http://clinicaltrials.gov/ct2/show/NCT01395069. Accessed June 1, 2012
19. M. Nardi, I. Cunliffe, J. Cano, B. Cochener, R. Notivol, and T. Wiernas Nepafenac 0.1% compared to ketorolac 0.5% and placebo in cataract surgery IOVS 48 2007 ARVO E-Abstract 5438